Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (noted as Insight Molecular Diagnostics Inc. in metadata) on November 15, 2017. The filing reports the appointment of a new Chief Financial Officer and the terms of his compensatory arrangement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Base Salary: $330,000 annually.
- Stock Options: Grant of 200,000 shares at an exercise price of $5.90 per share.
- Option Vesting: 25% vests after one year; the remainder vests in 36 equal monthly installments thereafter.
- Performance Bonus: Eligible for up to 40% of base salary, subject to Board approval.
- Severance: Six months' base salary for termination without cause after August 1, 2018; twelve months' base salary if termination occurs within 12 months of a change of control.
Material Changes
The primary material change is the appointment of Mitchell Levine as Chief Financial Officer, effective November 15, 2017. Mr. Levine succeeds Russell Skibsted, who served as CFO under a Shared Facilities and Services Agreement with OncoCyte's former parent company, BioTime, Inc. Mr. Skibsted remains the CFO of BioTime.
Outlook, Risks, and Management Commentary
The filing includes standard forward-looking statements disclaiming obligations to update future projections. It notes that actual results may differ materially from anticipated results due to risk factors detailed in the company's Form 10. No specific operational guidance or financial outlook is provided in this document.
Investor Verification Checklist
- Verify the full terms of the Employment Agreement, which is expected to be filed as an exhibit to the Form 10-K for the year ending December 31, 2017.
- Confirm the vesting schedule and exercise terms of the 200,000 stock options granted to the new CFO.
- Review the "Risk Factors" section of the company's Form 10 for details on potential deviations from forward-looking statements.
- Monitor for the potential additional grant of 50,000 shares in 2018, subject to Board approval.